What was the major news announced by Beamtree (ASX:BMT) regarding Saudi Arabia?

Beamtree secured a $2 million, 12-month contract with the Fakeeh Care Group to provide clinical coding, auditing, and analytics support for Dr Soliman Fakeeh Hospitals. This deal is a strategic win for the company’s Middle Eastern expansion, as it aligns with Saudi Arabia’s national healthcare funding reforms.

Why did Beamtree (ASX:BMT) withdraw its FY26 growth guidance?

The company withdrew its double-digit Annual Recurring Revenue (ARR) guidance for FY26 to prioritize "high-quality revenue conversion" over aggressive volume. This move stems from a strategic review that tightened sales pipeline discipline, acknowledging that several active opportunities may not close before the end of the financial year.

What is the "cost base reset" mentioned by Beamtree management?

Beamtree is implementing a plan to align its total cash operating costs with its actual revenue trajectory by July 1, 2026. This "reset" involves cutting investment in underperforming products and focusing resources on high-growth lines like RippleDown and PICQ.

How does the Fakeeh Care Group contract fit into Beamtree's long-term strategy?

While the $2 million contract is currently project-based rather than recurring, Beamtree views it as a "bridge" to future Software-as-a-Service (SaaS) revenue. By embedding its coding and analytics services within a major Saudi hospital group, the company aims to convert these services into long-term, high-margin subscriptions.

What are the main bull and bear points for Beamtree (ASX:BMT) after this update?

The bull case rests on the company’s successful expansion into the lucrative Saudi market and its disciplined pivot toward profitability and high-margin products. The bear case highlights the withdrawal of FY26 guidance and the execution risk associated with the "cost base reset."

Beamtree wins $2M Saudi contract amid strategic reset

Written by Isaac FrancisPublished May. 5 2026Last Updated May. 5 2026

Health technology firm Beamtree (ASX:BMT) announced a pivotal $2 million contract with Saudi Arabia’s Fakeeh Care Group, sending its share price up over 9% as the company undergoes a rigorous strategic overhaul.

The twelve-month agreement involves providing sophisticated clinical coding, auditing, and analytics support for Dr Soliman Fakeeh Hospitals, a premier listed healthcare provider operating multiple medical centres across the kingdom.

The engagement marks a significant milestone in Beamtree’s Middle Eastern expansion, aligning with Saudi Arabia’s sweeping national reforms in clinical funding and reimbursement.

By delivering a mix of on-site and remote services, Beamtree aims to transition this project-based work into long-term software-as-a-service recurring revenue, leveraging its established reputation following previous audits for the Saudi Centre for National Health Insurance.

The board has accelerated a "cost base reset" to synchronise operating expenses with revenue growth by July.

The fiscal discipline is part of a broader review designed to achieve cash operating profit break-even by the 2027 financial year.

As a result, Beamtree is narrowing its investment focus towards high-growth product lines—such as its RippleDown diagnostic support and PICQ coding platforms—while withdrawing previous FY26 double-digit growth guidance to prioritise high-quality revenue conversion.

At the time of reporting, Beamtree’s share price was $0.10.